51458-66-3

Usage

Uses

Used in Organic Synthesis:
(3-Aminophenyl)(4-aminophenyl)methanone is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In pharmaceutical research, (3-Aminophenyl)(4-aminophenyl)methanone is employed as a building block for the development of new drugs. Its amine groups can be modified to create a range of bioactive compounds with potential therapeutic applications. (3-Aminophenyl)(4-aminophenyl)methanone's potential biological activities, combined with its structural features, make it a promising candidate for the design of novel pharmaceutical agents.
Used in Chemical Research:
(3-Aminophenyl)(4-aminophenyl)methanone is also used in chemical research to study the properties of similar compounds and to understand the reactivity and behavior of aromatic amine and methanone groups. This knowledge can contribute to the advancement of synthetic methodologies and the development of new chemical processes.
Note: Since the provided materials do not specify particular industries or detailed applications, the uses listed above are general and based on the potential of the compound as described. Further research would be required to identify specific applications in various industries.

InChI:InChI=1/C13H12N2O/c14-11-6-4-9(5-7-11)13(16)10-2-1-3-12(15)8-10/h1-8H,14-15H2

Upstream product

• 1144-74-7 4-nitrobenzophenone 
• 87424-32-6 4-bromo-3,4'-dinitro benzophenone 
• 37567-38-7 4-chloro-3,4'-dinitro benzophenone 
• 107-06-2 1,2-dichloro-ethane 
• 98-95-3 nitrobenzene 
• 3002-33-3 4-(3'-nitrobenzyl)-nitrobenzene 

Downstream Products

• 611-81-4 (3-hydroxyphenyl)(4-hydroxyphenyl)methanone 
• 83699-50-7 3,4'-bis-acetylamino-benzophenone 
• 71969-94-3 C₂₆H₂₄N₆ 

Relevant academic research and scientific papers

Guanidinium-based derivatives: Searching for new kinase inhibitors

Considering the structural similarities between the kinase inhibitor sorafenib and 4,4′-bis-guanidinium derivatives previously prepared by Rozas and co., which display interesting cytotoxicity in cancer cells, we have studied whether this activity could result from kinase inhibition. Five new families have been prepared consisting of unsubstituted and aryl-substituted 3,4′-bis-guanidiniums, 3,4′-bis-2-aminoimidazolinium and 3-acetamide-4′-(4-chloro-3-trifluoromethylphenyl)guanidinium derivatives. Cytotoxicity (measuring the IC50 values) and apoptosis studies in human HL-60 promyelocytic leukemia cells were carried out for these compounds. Additionally, their potential inhibitory effect was explored on a panel of kinases known to be involved in apoptotic pathways. The previously prepared cytotoxic 4,4′-bis-guanidiniums did not inhibit any of these kinases; however, some of the novel 3,4′-substituted derivatives showed a high percentage inhibition of RAF-1/MEK-1, for which the potential mode of binding was evaluated by docking studies. The interesting antitumour properties showed by these compounds open up new exciting lines of investigation for kinase inhibitors as anticancer agents and also highlights the relevance of the guanidinium moiety for protein kinase inhibitors chemical design.

Process for preparation of 3,3'- or 3,4'-diamino benzophenone

3,3'- or 3,4'-diamino benzophenone is prepared by catalytically reducing and dehalogenating, in the presence of a reduction catalyst and a dehydrohalogenation agent, a benzophenone compound or benzophenone compounds of the general formula STR1 in which X is a halogen atom at position 2 or 4 of the benzene ring and Y is hydrogen or a halogen atom and in which the nitro group is at position 3' or 4' of the benzene ring if Y is hydrogen, while Y is at position 4' and the nitro group is at position 3' of the benzene ring if Y is a halogen atom.